Cervical Cancer
Conditions
Keywords
para-aortic lymph nodes
Brief summary
Recent studies have shown that the chance of survival among women with advanced cervical cancer is increased when they receive concurrent chemotherapy and radiation to the pelvis. However, patients who have advanced disease show loco-regional failure as well as a high incidence of distant metastasis. Positron emission tomography (PET) scanning has high sensitivity and specificity in the detection of pelvic and para-aortic lymph node metastases. While the detection of para-aortic metastases by PET significantly impacts prognosis, PET has been known to show positive lymph node metastasis in the pelvis only while not detecting micrometastatic disease in the para-aortic lymph nodes (despite the fact that they are histologically known). In addition, patients with positive para-aortic lymph nodes on PET, greater amounts (more than 45 Gy) of radiation must be used to improve the probability of controlling the cancer. However, doses greater than this have been limited because of the dose and volume limits to the small bowel. But, Intensity Modulated Radiation Therapy (IMRT) is a new way of calculating and delivering radiation therapy. Compared to external beam radiation, IMRT has the improved ability to deliver large doses of radiation to specific targets while minimizing the exposure to surrounding normal tissue. With IMRT, however, the effective dose/volume can be increased more safely and lower the toxicity of surrounding tissue, thus making prophylactic dosing to para-aortic lymph nodes not detected by PET safer and more effective.
Detailed description
Prior to entrance on the study, patients will undergo a history and physical and evaluation of Karnofsky Performance Status. They will have a biopsy of their tumor and will undergo a fluorodeoxyglucose (FDG) PET scan and must include evaluation of para-aortic lymph nodes. Blood work will be done (complete blood count (CBC), differential, platelets, blood urea nitrogen(BUN), serum creatinine, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Also, pre-treatment, patients will receive a chest x-ray and an intravenous push (IVP) (unless a computed tomography (CT) with contrast has been performed). Additionally, patient may undergo a CT, magnetic resonance (MRI) and/or lymphangiogram. Patients will then be registered to a treatment arm, depending on the outcome of their PET scan. Patients with positive pelvic lymph nodes but no positive para-aortic lymph nodes by PET will be assigned to Treatment Arm 1. Patients with positive pelvic lymph nodes and positive para-aortic lymph nodes by PET will be assigned to treatment arm 2. Treatment Group 1. Either a conventional or CT simulation may be performed. Patients will be treated with IMRT extended field external beam radiation therapy (to cover pelvis and para-aortic lymph nodes) and intracavitary radiation (6 high dose radiation (HDR) treatments) concurrently with cisplatin (40 mg/m\^2/week) Treatment Group 2. A CT simulation must be performed. Patients will be treated with extended field external beam radiation therapy to the pelvis and with IMRT to cover the para-aortic lymph nodes to 60 Gy, 50.4 Gy to the para-aortic lymph node bed in conjunction with external beam pelvic radiation therapy as appropriate for disease stage and intracavitary radiation (6 HDR treatments) concurrently with cisplatin (40 mg/m\^2/week).
Interventions
RADIATIONIMRT extended field external beam radiation therapy
RADIATIONBrachytherapy
DRUGCisplatin
Sponsors
Washington University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have carcinoma of the uterine cervix. * Patients with squamous cell, adenocarcinoma, and adenosquamous carcinoma are eligible. * International Federation of Gynecology and Obstetrics (FIGO) Stage I to IVA * Patients must have no evidence of metastatic disease outside of the pelvis (except to the para-aortic nodes), by PET. * Patients must have a Karnofsky Performance Status of \>= 60 and no medical contraindications to the administration of chemotherapy. * Age \>= 18. * Adequate bone marrow function: white blood cells (WBC) \>= 4000/mm3, platelets \>= 100,000 mm3. * Adequate renal function: BUN \<= 25 mg/dl, creatinine \<= 1.2 mg/dl (urinary diversion is permitted to improve renal function). * Patients must have bilirubin \<= 1.5 mg/dl. * Signed study-specific informed consent.
Exclusion criteria
* No positive lymph nodes by FDG PET * Positive supraclavicular lymph nodes by FDG PET Scan or evidence of more distant disease. * FIGO Stage IVB+ Cervical Cancer * No prior (within 5 years) or simultaneous malignancies (other than cutaneous basal cell carcinoma). * Karnofsky Performance Status \<60. * Patients with significant medical illness preventing the use of full dose chemotherapy are excluded. * Patients with the following histologies are excluded: small cell, carcinoid, glassy cell, clear cell and adenoid cystic. * Life expectancy \< 6 months. * Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL) are not eligible. * No prior surgery for treatment of disease other than exploratory laparotomy or biopsy. * No previous systemic chemotherapy. * No pelvic radiation therapy is permitted other than transvaginal irradiation to control bleeding. * Pregnant women are ineligible and those of child-bearing potential should practice contraception. * Patients with abnormal liver function tests
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | 1 year post start of radiation therapy | -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. |
| Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | 30 days after completion of radiation therapy | — |
| Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | 1st PET scan after completion of treatment (approximately month 6) | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of IMRT to the Para-aortic Lymph Nodes, IMRT External Beam Radiotherapy to the Pelvis, Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by the Frequency of Distant Metastasis | 5 years after completion of radiation therapy |
Countries
United States
Participant flow
Recruitment details
The study opened to patient accrual on 05/01/2003 and closed to patient accrual on 04/24/2008.
Participants by arm
| Arm | Count |
|---|---|
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) Pelvic Lymph Nodes Only Positive on FDG PET.
IMRT External Beam radiation to the para-aortic region (45 Gy)
Pelvis intracavitary brachytherapy (6 HDR treatments)
Weekly cisplatin 40 mg/m\^2 | 41 |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) Para-Aortic Lymph Nodes Positive on FDG PET
IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)
IMRT external beam pelvic radiation therapy as appropriate for stage
Intracavitary brachytherapy (6 HDR treatments)
Weekly cisplatin (40 mg/m\^2) | 20 |
| Total | 61 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Did not receive chemo per protocol | 1 | 0 |
| Overall Study | Did not sign consent form | 0 | 1 |
| Overall Study | Ineligible | 1 | 0 |
| Overall Study | Non-compliant | 0 | 2 |
| Overall Study | Poor performance status | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Total |
|---|---|---|---|
| Age, Continuous | 45 years | 52 years | 45 years |
| Region of Enrollment United States | 41 participants | 20 participants | 61 participants |
| Sex: Female, Male Female | 41 Participants | 20 Participants | 61 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 41 / 41 | 20 / 20 |
| serious Total, serious adverse events | 10 / 41 | 4 / 20 |
Outcome results
Primary
Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status
Time frame: 1st PET scan after completion of treatment (approximately month 6)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | Negative PET scan | 27 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | Equivocal PET scan | 6 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | PET scan not performed | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | Positive PET scan | 6 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | Positive PET scan | 9 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | Negative PET scan | 7 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | PET scan not performed | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status | Equivocal PET scan | 4 participants |
Primary
Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher)
Time frame: 30 days after completion of radiation therapy
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Absolute neutrophil count | 6 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Anorexia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Anxiety | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Diarrhea | 5 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Dysuria | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Fatigue | 9 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Infection (Urinalysis) | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Leukopenia | 10 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Pain - not otherwise specified (NOS) | 4 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | packed red blood cell (PRBC) Transfusion | 5 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Platelets | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Proteinuria | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Skin | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Vomiting | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Weight loss | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Creatinine | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Vaginal mucosa erythematous | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Prothrombin time (PT) | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | partial thromboplastin time (PTT) | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Renal failure | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | aspartate aminotransferase (ALT) | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Dyspnea | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Granulocytes/bands | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hemoglobin | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hematocrit | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Vaginal bleeding | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hyperglycemia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypermagnesemia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypertension | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypocalcemia | 3 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypokalemia | 5 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hyponatremia | 3 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypomagnesemia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Infection with neutropenia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Lymphopenia | 35 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Nausea | 4 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Abdominal pain | 3 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Pelvic pain | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Albumin | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Atrial fibrillation | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Confusion | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Edema | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | erythrocyte sedimentation rate (ESR) | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hyperkalemia | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypoglycemia | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | international normalized ratio (INR) | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Leucocyte esterase | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Yeast infection | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Leucocyte esterase | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Absolute neutrophil count | 4 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hematocrit | 4 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Anorexia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Abdominal pain | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Anxiety | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Vaginal bleeding | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | erythrocyte sedimentation rate (ESR) | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Dysuria | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hyperglycemia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Fatigue | 4 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Infection with neutropenia | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Pelvic pain | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Infection (Urinalysis) | 3 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypermagnesemia | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | international normalized ratio (INR) | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Pain - not otherwise specified (NOS) | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypertension | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | packed red blood cell (PRBC) Transfusion | 11 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Albumin | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Platelets | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypocalcemia | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Proteinuria | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hyperkalemia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Skin | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypokalemia | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Vomiting | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Atrial fibrillation | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Weight loss | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hyponatremia | 4 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Creatinine | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Yeast infection | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Vaginal mucosa erythematous | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypomagnesemia | 5 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Prothrombin time (PT) | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Confusion | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | partial thromboplastin time (PTT) | 4 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Leukopenia | 10 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Renal failure | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hypoglycemia | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | aspartate aminotransferase (ALT) | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Diarrhea | 5 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Lymphopenia | 25 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Dyspnea | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Edema | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Granulocytes/bands | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Nausea | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher) | Hemoglobin | 6 participants |
Primary
Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity
-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting.
Time frame: 1 year post start of radiation therapy
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Anorexia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Dyspnea | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hemoglobin | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Fatigue | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Diarrhea | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hematocrit | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Platelets | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hyperkalemia | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hypomagnesemia | 1 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hypoglycemia | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Neutropenia | 3 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hyponatremia | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Leukopenia | 2 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Infection without neutropenia | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Renal failure | 0 participants |
| Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Lymphopenia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Renal failure | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Infection without neutropenia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Neutropenia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Anorexia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Diarrhea | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hypomagnesemia | 0 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Leukopenia | 3 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Lymphopenia | 3 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Dyspnea | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hemoglobin | 2 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hematocrit | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hyperkalemia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hypoglycemia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Hyponatremia | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Platelets | 1 participants |
| Treatment Group 2 (IMRT, Brachytherapy, Cisplatin) | Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity | Fatigue | 1 participants |
Secondary
Efficacy of IMRT to the Para-aortic Lymph Nodes, IMRT External Beam Radiotherapy to the Pelvis, Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by the Frequency of Distant Metastasis
Time frame: 5 years after completion of radiation therapy
Population: The data was not collected for this secondary outcome. Due to the the early termination of this study, only data for the primary outcomes were collected and analyzed.